久久视频在线视频精品-日韩亚洲变态另类中文-free性欧美69巨大-mm131巨爆乳美女少妇动态图

Endovastec? announced that its Talos? Thoracic Stent Graft System (Talos?) has recently received marketing approval in Brazil and Argentina, marking an important milestone in the company’s global strategy and its commitment to improving patient access to advanced aortic therapies. 

Talos? is a next-generation straight thoracic stent graft system, and the world’s first “breathing” stent graft specifically designed for the treatment of Stanford type B aortic dissection. It can improve the reshaping of the distal true lumen by extending the stent length. Its unique distal honeycomb design (length can be selected from 0 mm to 200 mm) can enlarge the distal true lumen diameter of the thoracic aorta, reduce the possibility of spinal cord ischemia caused by overlying intercostal arteries, and improve the long-term treatment outcomes. With a maximum stent length of 260 mm, Talos? is designed to optimize aortic remodeling outcomes in complex cases.

Latin America represents a key region in Endovastec?’s global footprint. The company’s aortic product portfolio is already in clinical use across several countries in this region, including Brazil, Argentina, Colombia, and Mexico. The approval of Talos? in Brazil and Argentina will further reinforce the company’s regional presence and broadens the range of innovative treatment options available to patients with aortic disease.